LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Inicio・Lista de Acciones・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

14.35 5.44

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

13.55

Máximo

14.37

Métricas clave
By Trading Economics
Ingresos	227M
Ventas	139M
P/B Media del Sector	5.196 61.417
Margen de beneficios	163.843
Empleados	1,780
EBITDA	1.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+43.99% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.5B
Apertura anterior	8.91
Cierre anterior	14.35

Noticias sobre sentimiento de mercado

By Acuity

50%

147 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

14.24 / 14.78 Soporte y Resistencia

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 mar 2026, 19:18 UTC

Principales Movimientos del Mercado

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11 mar 2026, 23:54 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

11 mar 2026, 23:54 UTC

Charlas de Mercado

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11 mar 2026, 23:51 UTC

Charlas de Mercado

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11 mar 2026, 23:41 UTC

Charlas de Mercado

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11 mar 2026, 23:37 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11 mar 2026, 23:17 UTC

Noticias de Eventos Importantes

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11 mar 2026, 23:17 UTC

Noticias de Eventos Importantes

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11 mar 2026, 22:29 UTC

Charlas de Mercado

Australia Shares Set to Fall in Early Trade -- Market Talk

11 mar 2026, 21:47 UTC

Ganancias

Liontown Resources: Market Tailwinds Strengthening Outlook

11 mar 2026, 21:46 UTC

Ganancias

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11 mar 2026, 21:45 UTC

Ganancias

Liontown Resources Says FY26 Guidance Unchanged

11 mar 2026, 21:45 UTC

Ganancias

Liontown Resources 1H Unit Operating Costs A$985/Ton

11 mar 2026, 21:44 UTC

Ganancias

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11 mar 2026, 21:43 UTC

Ganancias

Liontown Resources 1H Revenue A$207.5 Million

11 mar 2026, 21:43 UTC

Ganancias

Liontown Resources 1H Net Loss A$184 Million

11 mar 2026, 21:12 UTC

Adquisiciones, fusiones, absorciones

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11 mar 2026, 21:10 UTC

Ganancias

Vista Gold FY25 Loss $7.5M >VGZ

11 mar 2026, 21:10 UTC

Ganancias

Vista Gold FY25 Loss/Shr 6c >VGZ

11 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

11 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

11 mar 2026, 20:27 UTC

Adquisiciones, fusiones, absorciones

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11 mar 2026, 20:26 UTC

Ganancias

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11 mar 2026, 20:19 UTC

Noticias de Eventos Importantes

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11 mar 2026, 20:15 UTC

Ganancias

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11 mar 2026, 20:12 UTC

Noticias de Eventos Importantes

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11 mar 2026, 19:31 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11 mar 2026, 19:01 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11 mar 2026, 18:59 UTC

Adquisiciones, fusiones, absorciones

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11 mar 2026, 18:43 UTC

Noticias de Eventos Importantes

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

43.99% repunte

Estimación a 12 Meses

Media 20 USD 43.99%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

14.24 / 14.78Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

147 / 351 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.